Pfizer Rating Reiterated by Jefferies Group (PFE)
Pfizer (NYSE:PFE)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group in a research report issued on Friday, AmericanBankingNews.com reports.
Pfizer (NYSE:PFE) traded up 0.09% on Friday, hitting $28.795. The stock had a trading volume of 11,083,840 shares. Pfizer has a one year low of $23.55 and a one year high of $31.15. The stock’s 50-day moving average is $28.5 and its 200-day moving average is $28.87. The company has a market cap of $190.6 billion and a P/E ratio of 7.98.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was down 7.1% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.16 earnings per share for the current fiscal year.
PFE has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Pfizer in a research note to investors on Tuesday. They set an “outperform” rating and a $34.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Pfizer from $33.00 to $34.00 in a research note to investors on Friday, September 27th. They now have an “overweight” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Pfizer to $28.50 in a research note to investors on Tuesday, September 3rd. They now have a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Buy” and a consensus price target of $30.92.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.